Annual Report and Accounts 2019
20 March 2020
Oakley Capital Investments Limited
Annual Report and Accounts 2019
Oakley Capital Investments Limited1(the "Company") announces that further to the announcement of the Company's preliminary annual results on 12 March 2020, the Company has today published its audited Annual Report and Accounts for the year ended 31 December 2019 on the Company's website.
- ends -
For further information please contact:
Oakley Capital Limited
+44 20 7766 6900
Steven Tredget, Investor Relations
Greenbrook Communications Limited
+44 20 7952 2000
Alex Jones / Gina Bell / James Williams
Liberum Capital Limited (Financial Adviser & Broker)
+44 20 3100 2000
Gillian Martin / Owen Matthews
LEI Number: 213800KW6MZUK12CQ815
1 About Oakley Capital Investments Limited ("OCI")
OCI is a Specialist Fund Segment ("SFS") traded investment vehicle, which provides access to the Oakley Funds2. It is a liquid vehicle that aims to provide capital growth and dividends to investors.
The Oakley Funds
Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III and Oakley Capital IV, are unlisted mid-market private equity funds with the aim of providing investors with significant long-term capital appreciation. The investment strategy of the funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement.
The Investment Adviser
Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.
Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules. The London Stock Exchange has not examined or approved the contents of the Prospectus.
The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Kallelse till extra bolagsstämma i NanoCap Group AB
Aktieägare som vill delta i stämman ska dels vara upptagen i utskrift av aktieboken avseende förhållandena den 24 oktober 2023, dels anmäla sig till bolaget senast den 27 oktober 2023 skriftligen till Box 5141, 102 43 Stockholm eller via e-post till [email protected]. Anm...
Bioextrax: Capacity to accommodate rising interest
American start-up company exercises option for the next periodWarrants subscription adds SEK 10.6 million before issue costsOur model implies a fair valuation of SEK 10.5 per shareBioextrax shows continued progress in its Q2 report for 2023. The company signed a license agreement with the US start-u...